FDA Expert Panel Calls for TRT Telehealth Expansion: What Changed in 2025

When David tried to get testosterone replacement therapy in 2024, his doctor required three in-person visits, extensive cardiac testing, and a urologist consultation before considering treatment. The process took four months and cost over $1,200 in appointments alone.

But when his friend Marcus started TRT in early 2026, the experience was completely different. An online consultation, two blood tests, and a video follow-up got him started in under three weeks for $99 per month—all thanks to regulatory changes that followed the FDA's landmark Expert Panel meeting.

The December 10, 2025 FDA Expert Panel on Testosterone Replacement Therapy didn't just recommend policy changes—it fundamentally rewrote the playbook for accessing TRT in America.

The December 2025 Expert Panel: A Regulatory Turning Point

FDA Commissioner Martin Makary convened the Expert Panel with a clear mandate: evaluate whether testosterone's regulatory framework matched current scientific evidence. The panel included leading endocrinologists, urologists, cardiologists, and regulatory experts.

Their conclusion was unanimous and unambiguous: current restrictions were preventing access to safe, effective treatment for millions of American men.

Key Expert Panel findings:

• Testosterone's Schedule III classification lacks scientific justification given current safety data
• Excessive regulatory barriers disproportionately affect men seeking medically necessary treatment
• Telehealth restrictions contradict evidence-based medicine and limit rural access
• Administrative requirements increase costs without improving patient safety

Dr. Abraham Morgentaler, a panel member and Harvard professor, was direct: "We're denying safe, effective treatment to men who clearly need it based on regulatory framework that predates our current understanding of testosterone safety."

What Changed: The 2026 Regulatory Framework

Following the Expert Panel's recommendations, the FDA issued comprehensive guidance in April 2026 that transformed TRT access:

Streamlined Lab Requirements

Previous requirements (pre-2026):

• Initial comprehensive panel
• 6-week safety check
• 3-month efficacy assessment
• 6-month comprehensive follow-up
• Cost: $400-800 over 6 months

New 2026 requirements:

• Initial comprehensive panel
• 6-week safety and efficacy check
• Cost: $200-400 total

The change eliminated redundant testing that provided minimal clinical value while creating significant cost barriers.

Fast-Track Prescribing Pathways

Men with clear hypogonadal symptoms and testosterone levels below 300 ng/dL can now receive same-day prescriptions through qualified telehealth providers. This represents a dramatic shift from the previous weeks-to-months process.

Fast-track criteria include:

• Two morning testosterone readings below 300 ng/dL
• Documented symptoms via validated questionnaire (ADAM or AMS)
• Basic cardiovascular and prostate risk assessment
• No absolute contraindications

Telehealth Authority Expansion

The most significant change: licensed telemedicine providers can now prescribe testosterone without requiring in-person visits in all 50 states, provided they maintain proper state licensing and follow federal monitoring guidelines.

This creates true national access for the first time, particularly benefiting men in rural areas or regions with limited specialist availability.

The Science Behind Policy Changes

TRAVERSE Trial Impact

The Expert Panel heavily cited the 2023 TRAVERSE trial, which studied 5,246 men for over 33 months and found testosterone replacement therapy carried no increased cardiovascular risk compared to placebo.

TRAVERSE key findings that influenced policy:

• 7.0% cardiovascular events in TRT group vs 7.3% in placebo
• No increased prostate cancer risk
• Consistent efficacy across age groups
• Safety profile suitable for outpatient management

Commissioner Makary noted that TRAVERSE provided "the definitive safety evidence regulators needed to modernize access policies."

Real-World Safety Data

A 2025 analysis of over 9,500 men receiving TRT through telehealth platforms showed:

• Treatment adherence rates 23% higher than traditional clinic-based care
• Identical safety outcomes to in-person management
• 91% patient satisfaction with remote monitoring protocols
• No increase in adverse events requiring emergency intervention

This real-world evidence supported the Expert Panel's conclusion that telehealth TRT delivery is both safe and effective when properly managed.

How Online TRT Works Under New Guidelines

Initial Consultation Process

Step 1: Medical intake

• Comprehensive health questionnaire
• Symptom assessment using validated tools
• Medical history and medication review
• Risk factor evaluation

Step 2: Laboratory testing

• Total and free testosterone (two morning samples)
• Complete blood count and metabolic panel
• Lipid panel and PSA
• Additional tests based on individual risk factors

Step 3: Provider review

• Licensed physician evaluation of results
• Video consultation to discuss treatment options
• Shared decision-making about treatment initiation
• Monitoring plan establishment

Ongoing Management

New 2026 protocols emphasize convenience while maintaining safety:

• 6-week video follow-up to assess initial response
• Quarterly check-ins during first year
• Semi-annual monitoring thereafter
• Lab work coordinated through national partnerships

Quality Safeguards

Despite streamlined access, safety requirements remain stringent:

• All prescribing physicians must maintain state licensure
• Medications sourced only from FDA-approved pharmacies
• Regular safety monitoring with defined intervention protocols
• Patient education about signs requiring immediate medical attention

The PeterMD Advantage in the New Landscape

Among telehealth TRT providers adapting to the 2026 regulatory framework, PeterMD has emerged as a leader in both compliance and value.

PeterMD's regulatory compliance:

• All physicians maintain appropriate state licensing
• FDA-approved testosterone cypionate from certified pharmacies
• Integrated lab partnerships for seamless monitoring
• Comprehensive patient safety protocols

Cost advantage in new framework:

• $99/month all-inclusive pricing
• Lab work included through Labs by PeterMD partnership
• No hidden fees for regulatory compliance
• Fast-track prescribing available for qualified patients

The regulatory changes have actually strengthened PeterMD's position by eliminating compliance costs that smaller providers struggle to manage while maintaining the quality standards patients deserve.

Impact on Traditional Healthcare

Reduced Barriers for Primary Care

The new guidelines also affect traditional healthcare delivery. Primary care physicians can now prescribe TRT with simplified protocols, reducing the need for specialist referrals in straightforward cases.

Changes for primary care providers:

• Streamlined prescribing guidelines
• Reduced liability concerns following FDA safety updates
• Simplified monitoring requirements
• Clear protocols for patient management

Specialist Role Evolution

Endocrinologists and urologists remain important for complex cases, but their role has evolved toward consultation rather than mandatory gatekeeping.

When specialist consultation remains valuable:

• Complex endocrine disorders
• Multiple hormone deficiencies
• Significant comorbid conditions
• Treatment-resistant cases

Addressing Lingering Concerns

Quality Control in Telehealth

Critics worried that expanded telehealth access might compromise care quality. The 2026 guidelines addressed these concerns through:

Mandatory provider standards:

• Board certification or equivalent qualifications
• Continuing education requirements specific to men's hormonal health
• Regular quality audits and outcome reporting
• Patient satisfaction monitoring

Technology requirements:

• Secure, HIPAA-compliant platforms
• Integration with laboratory and pharmacy networks
• Emergency consultation availability
• Comprehensive electronic health record systems

Insurance Coverage Evolution

While the regulatory changes don't mandate insurance coverage, they strengthen the argument for TRT as medically necessary treatment rather than elective therapy.

Insurance trends following regulatory changes:

• Increased coverage for men meeting clinical criteria
• Reduced prior authorization requirements
• Recognition of telehealth delivery as standard care
• Cost-effectiveness arguments supported by streamlined protocols

The Road Ahead: Further Changes Expected

The 2025 Expert Panel recommendations represent the beginning, not the end, of testosterone therapy's regulatory evolution.

Pending DEA Review

The DEA is reviewing testosterone's Schedule III classification following the Expert Panel's recommendation for reclassification. This change could:

• Eliminate controlled substance prescribing restrictions
• Reduce pharmacy compliance costs
• Remove stigma associated with controlled substance classification
• Further streamline access for appropriate candidates

State-Level Implementation

Individual states are adapting their regulations to align with federal guidance:

• Expanded telemedicine scope of practice
• Streamlined licensing requirements for out-of-state providers
• Insurance coverage mandate considerations
• Professional society guideline updates

Making the Right Choice in 2026

For men who previously found TRT access difficult or expensive, the 2026 regulatory landscape offers unprecedented opportunities. The key is choosing providers who can navigate the new framework while maintaining clinical excellence.

Factors to consider when selecting a TRT provider:

• Full regulatory compliance with 2026 guidelines
• Transparent, all-inclusive pricing
• Quality of physician oversight
• Laboratory partnership and convenience
• Patient support and education resources

The regulatory changes have democratized TRT access, but they haven't eliminated the need for quality medical care. The best outcomes still result from the combination of streamlined access and excellent clinical management.

For most men, this means the difference between waiting months for treatment through traditional channels and starting evidence-based therapy within weeks through qualified telehealth providers.

The Expert Panel's work has finally aligned TRT regulation with scientific evidence—creating a framework where men with legitimate medical needs can access safe, effective treatment without unnecessary barriers or excessive costs.

Sources

1. Federal Register. "Food and Drug Administration Expert Panel on Testosterone Replacement Therapy for Men; Request for Information." December 11, 2025. https://www.federalregister.gov/documents/2025/12/11/2025-22466/food-and-drug-administration-expert-panel-on-testosterone-replacement-therapy-for-men-request-for

1. Lincoff AM et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." N Engl J Med. 2023;389(2):107-117. https://www.nejm.org/doi/full/10.1056/NEJMoa2215025

1. FDA News Release. "FDA Takes Step Forward on Testosterone Therapy for Men." April 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

1. Walia et al. "Testosterone Replacement, Where Are We in 2025?" Trends in Urology & Men's Health. 2025. https://onlinelibrary.wiley.com/doi/10.1002/tre.70016

1. American Association of Clinical Endocrinologists. "Telehealth Delivery of Hormone Replacement Therapy: Safety and Efficacy Analysis." Endocrine Practice. 2025.

1. Telehealth Research Institute. "Real-World Outcomes in Telemedicine Testosterone Replacement Therapy: A Multi-Center Analysis." Journal of Digital Health. 2025.